Koup, Richard A.Pikora, Cheryl A.Mazzara, GailPanicali, DennisSullivan, John L.2022-08-232022-08-231991-01-012008-10-15<p>Viral Immunol. 1991 Winter;4(4):215-23.</p>0882-8245 (Print)10.1089/vim.1991.4.2151726398https://hdl.handle.net/20.500.14038/33971To determine if and when the antibody-dependent cell-mediated cytotoxic (ADCC) response of human serum exhibits broad reactivity across HIV-1 strains, multiple sera were tested for their ability to mediate ADCC against target cells infected with recombinant vaccinia vectors expressing envelope genes of HTLV-IIIB or HTLV-IIIRF. These vectors were found to express the envelope glycoproteins of the two HIV-1 strains and so were appropriate targets for ADCC assays. All the HIV-1-positive sera were able to mediate ADCC against both HTLV-IIIB and HTLV-IIIRF envelope-expressing targets at similar titer. In sera from early seroconverters, the ADCC response was again broadly reactive, even in those sera that exhibited strain-specific neutralizing antibody responses. The ADCC response to natural infection with HIV-1 is therefore broadly reactive and precedes the development of a broad neutralizing antibody response. The broad reactivity of HIV-1-specific ADCC responses may be important for protection against cell-associated virus in vaccine development.en-USAntibody Specificity; *Antibody-Dependent Cell Cytotoxicity; B-Lymphocytes; Cell Line; Epitopes; HIV; HIV Antibodies; HIV Envelope Protein gp120; HIV Envelope Protein gp41; HIV Seropositivity; HIV-1; Humans; Recombinant ProteinsLife SciencesMedicine and Health SciencesJournal Articlehttps://escholarship.umassmed.edu/gsbs_sp/623651093gsbs_sp/623